303 related articles for article (PubMed ID: 35317832)
1. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.
Yang H; Yan M; Li W; Xu L
J Transl Med; 2022 Mar; 20(1):140. PubMed ID: 35317832
[TBL] [Abstract][Full Text] [Related]
2. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
Lu JC; Zeng HY; Sun QM; Meng QN; Huang XY; Zhang PF; Yang X; Peng R; Gao C; Wei CY; Shen YH; Cai JB; Dong RZ; Shi YH; Sun HC; Shi YG; Zhou J; Fan J; Ke AW; Yang LX; Shi GM
Theranostics; 2019; 9(16):4678-4687. PubMed ID: 31367249
[No Abstract] [Full Text] [Related]
3. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer.
Giatromanolaki A; Mitrakas A; Anestopoulos I; Kontosis A; Koukourakis IM; Pappa A; Panayiotidis MI; Koukourakis MI
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406573
[TBL] [Abstract][Full Text] [Related]
5. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
6. Identification of macrophage correlated biomarkers to predict the prognosis in patients with intrahepatic cholangiocarcinoma.
Xu L; Yan M; Long J; Liu M; Yang H; Li W
Front Oncol; 2022; 12():967982. PubMed ID: 36158683
[TBL] [Abstract][Full Text] [Related]
7. Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic Factor in Stage I Lung Adenocarcinoma.
Yoshida C; Kadota K; Ibuki E; Ishikawa R; Haba R; Yajima T
Anticancer Res; 2024 Mar; 44(3):1289-1297. PubMed ID: 38423652
[TBL] [Abstract][Full Text] [Related]
8. Poor clinical outcomes and immunoevasive contexture in SIRPα
Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
[TBL] [Abstract][Full Text] [Related]
9. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma.
Koga N; Hu Q; Sakai A; Takada K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Oki E; Oda Y; Mori M
Cancer Sci; 2021 Aug; 112(8):3018-3028. PubMed ID: 34009732
[TBL] [Abstract][Full Text] [Related]
11. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.
Hasita H; Komohara Y; Okabe H; Masuda T; Ohnishi K; Lei XF; Beppu T; Baba H; Takeya M
Cancer Sci; 2010 Aug; 101(8):1913-9. PubMed ID: 20545696
[TBL] [Abstract][Full Text] [Related]
12. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
13. CD86
Sun D; Luo T; Dong P; Zhang N; Chen J; Zhang S; Liu L; Dong L; Zhang S
PeerJ; 2020; 8():e8458. PubMed ID: 32002338
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
Chen S; Zhan S; Ding S; Zhang Q; Xuan H; Zhang X; Cao L
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16609-16621. PubMed ID: 37715830
[TBL] [Abstract][Full Text] [Related]
16. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.
Xia T; Li K; Niu N; Shao Y; Ding D; Thomas DL; Jing H; Fujiwara K; Hu H; Osipov A; Yuan C; Wolfgang CL; Thompson ED; Anders RA; He J; Mou Y; Murphy AG; Zheng L
J Hematol Oncol; 2022 Mar; 15(1):37. PubMed ID: 35346322
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells
Brauneck F; Oliveira-Ferrer L; Muschhammer J; Sturmheit T; Ackermann C; Haag F; Schulze Zur Wiesch J; Ding Y; Qi M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Wellbrock J
Front Immunol; 2023; 14():1250258. PubMed ID: 37876933
[TBL] [Abstract][Full Text] [Related]
18. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Signal Regulatory Protein Alpha (SIRPα) Expression in Hepatocellular Carcinoma.
Tomiyama T; Itoh S; Iseda N; Toshida K; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Harada N; Liu YC; Ozaki D; Kohashi K; Oda Y; Mori M; Yoshizumi T
Ann Surg Oncol; 2023 Jun; 30(6):3378-3389. PubMed ID: 36641515
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
